Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company Announcement Phase III study of daratumumab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma Collaborative study between European...
-
Minneapolis, MN, April 28, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an...
-
In an analysis of pooled Phase 2/3 data, ZilrettaTM (FX006) demonstrated clinically meaningful pain relief and functional improvement in patients with osteoarthritisA separate Phase 2 study shows...
-
Personalized cellular immunotherapy designed to prevent transplant kidney rejection and eliminate the need for chronic anti-rejection drugs Single Phase 3 study will evaluate functional immune...
-
CHAPEL HILL, N.C., April 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
-
NEW YORK, April 28, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology...
-
Reports first quarter 2017 revenue of $5.2 millionReports first quarter 2017 GAAP diluted EPS of $(0.02) and non-GAAP diluted EPS of $0.00Announces $8 million share repurchase program WINTER SPRINGS,...
-
Company Announcement DARZALEX approved in Europe in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone in patients who have received at least one prior therapy...
-
Paris, le 28 avril 2017 Sanofi publie de solides résultats au premier trimestre 2017 T1 2017 Var. Variation (TCC) Variation (TCC/PC(1)) Chiffre d'affaires net IFRS publié ...
-
Paris, April 28, 2017 Sanofi Delivers Robust Q1 2017 Financial Results Q1 2017 Change Change at CER Change at CER and CS(1) ...
-
Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA - New action date for Kevzara U.S. BLA is May 22, 2017 - Paris, France...
-
Sanofi et Regeneron annoncent que la FDA des États-Unis a accepté la resoumission et le réexamen de la demande de licence de produit biologique pour Kevzara® (sarilumab) - La date cible de la...
-
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Richard A. King as Chief Operating Officer, reporting to Gregory...
-
-- First quarter 2017 EXONDYS 51 total net revenues of $16.3 million -- -- Company anticipates net revenues for the year will exceed $95 million -- CAMBRIDGE, Mass., April 27, 2017 (GLOBE...
-
COLORADO SPRINGS, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”) today reported financial results for the three months ended March 31,...
-
Data Monitoring Committee for VITALITY-ALS Recommended Continuation of Phase 3 Trial; Results Expected in Q4 Sale of Royalty on Omecamtiv Mecarbil to Royalty Pharma Contributed to Increased...
-
Basel, Switzerland, April 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2016, shareholders approved all...
-
Basel, 27. April 2017 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die Aktionäre an der diesjährigen ordentlichen Generalversammlung für das Geschäftsjahr 2016 allen vom...
-
BROSSARD, QUÉBEC--(Marketwired - 27 avril 2017) - DIAGNOS inc. (« DIAGNOS » ou la « Société ») (TSX CROISSANCE:ADK), un leader dans la détection...
-
Extension to the USA of the Sarcopenia clinical programConfirmation of the good safety profile of Sarconeos in SARA-PK clinical trialAuthorizations to launch SARA-OBS clinical study, in which...
-
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company"), announced the following: The Company has signed a letter of intent with DMR...
-
ALISO VIEJO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., today announced new data demonstrating that the proprietary SCOUT® radar localization system significantly reduces...
-
SCOTTSDALE, AZ--(Marketwired - Apr 27, 2017) - KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises that in an open-label Phase II study of Hepko-V5 oral immunotherapeutic vaccine conducted in 75...
-
DEL MAR, CA--(Marketwired - Apr 27, 2017) - Del Mar dermatologist Deborah H. Atkin, MD is the first in the area to offer JUVÉDERM VOLLURE®, a newly FDA-approved dermal filler from the...
-
IRVINE, CA--(Marketwired - Apr 27, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it...
-
SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic data for SB204, a once-daily, topical monotherapy for...
-
REDONDO BEACH, CA--(Marketwired - Apr 27, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of...
-
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...
-
QUÉBEC, QUÉBEC--(Marketwired - 27 avril 2017) - NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS Benoit Chotard,...
-
QUÉBEC CITY, QUÉBEC--(Marketwired - April 27, 2017) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Benoit Chotard,...
-
PLANO, Texas, April 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the...
-
WIXOM, Mich., April 27, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
-
MADISON, Wis., April 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces preclinical...
-
NOVATO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
-
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...
-
HORSHAM, Pa., April 27, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (“STRATA”), a medical technology company dedicated to developing, commercializing, and marketing innovative...
-
NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers,...
-
FORT LAUDERDALE, Fla., April 27, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading provider of clinical data management technology, recently signed two additional contracts to...
-
Ocean View, Delaware, April 27, 2017 (GLOBE NEWSWIRE) -- Lactic Acid Market is set to exceed USD 6 billion by 2024. Polylactic Acid (PLA) Market size is set to exceed USD 4 billion by 2024;...
-
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research,...
-
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
-
SALT LAKE CITY and BOULDER, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration...
-
OMER, ISRAEL--(Marketwired - Apr 27, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization...
-
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s...
-
EWING, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank...
-
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration...
-
NEW YORK and LONDON, April 27, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison...
-
BIRKEROD, Denmark, April 27, 2017 (GLOBE NEWSWIRE) -- Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3C Patch Centrifuge. This new...
-
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting...